These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19388875)

  • 1. Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.
    Sleiman SF; Basso M; Mahishi L; Kozikowski AP; Donohoe ME; Langley B; Ratan RR
    Expert Opin Investig Drugs; 2009 May; 18(5):573-84. PubMed ID: 19388875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
    Dekker FJ; van den Bosch T; Martin NI
    Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.
    Mai A; Rotili D; Valente S; Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3940-57. PubMed ID: 19751207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
    Sharma S; Sarathlal KC; Taliyan R
    CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of HDAC and HAT genes in atrophying skeletal muscle.
    Beharry AW; Judge AR
    Muscle Nerve; 2015 Dec; 52(6):1098-101. PubMed ID: 26372908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of histone deacetylase inhibitors on kidney disease.
    Chun P
    Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
    Gray SG; Dangond F
    Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
    Ma X; Ezzeldin HH; Diasio RB
    Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production.
    Toussirot E; Abbas W; Khan KA; Tissot M; Jeudy A; Baud L; Bertolini E; Wendling D; Herbein G
    PLoS One; 2013; 8(8):e70939. PubMed ID: 24039666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors.
    Thomas EA
    Mol Neurobiol; 2009 Aug; 40(1):33-45. PubMed ID: 19396637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.